Cargando…
Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
Currently, the relationship between nutritional indices and the prognosis of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) remains unclear. This study aims to investigate the prognostic value of psoas muscle index (PMI)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512869/ https://www.ncbi.nlm.nih.gov/pubmed/37728115 http://dx.doi.org/10.1080/21645515.2023.2258567 |
_version_ | 1785108451813228544 |
---|---|
author | Luo, Ning Li, Hu Luo, Yindeng Hu, Peng Liang, Luwen Zhang, Rong Zhang, Dazhi Cai, Dachuan Kang, Juan |
author_facet | Luo, Ning Li, Hu Luo, Yindeng Hu, Peng Liang, Luwen Zhang, Rong Zhang, Dazhi Cai, Dachuan Kang, Juan |
author_sort | Luo, Ning |
collection | PubMed |
description | Currently, the relationship between nutritional indices and the prognosis of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) remains unclear. This study aims to investigate the prognostic value of psoas muscle index (PMI), prognostic nutritional index (PNI), body mass index (BMI), and geriatric nutritional risk index (GNRI) in HCC patients treated with ICIs combined with TKIs. A total of 124 male patients with HCC were included in this study. PNI, PMI, BMI, and GNRI were calculated at the beginning of treatment. The Cox proportional hazards model was used to analyze the effect of various variables. In the univariate analysis, PMI, PNI, GNRI, and ALB were found to impact the outcomes of the patients at different follow-up times. However, the predictive value of these nutritional indices was eliminated when established risk factors were considered. In the multivariate analysis that only included nutrition-related indicators, PMI emerged as an independent prognostic factor for 1-year treatment outcomes. The group with low PMI (≤5.5409 cm(2)/m(2)) was found to have a higher risk of death at one year and at the end of the follow-up period. |
format | Online Article Text |
id | pubmed-10512869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-105128692023-09-22 Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors Luo, Ning Li, Hu Luo, Yindeng Hu, Peng Liang, Luwen Zhang, Rong Zhang, Dazhi Cai, Dachuan Kang, Juan Hum Vaccin Immunother Research Article Currently, the relationship between nutritional indices and the prognosis of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) remains unclear. This study aims to investigate the prognostic value of psoas muscle index (PMI), prognostic nutritional index (PNI), body mass index (BMI), and geriatric nutritional risk index (GNRI) in HCC patients treated with ICIs combined with TKIs. A total of 124 male patients with HCC were included in this study. PNI, PMI, BMI, and GNRI were calculated at the beginning of treatment. The Cox proportional hazards model was used to analyze the effect of various variables. In the univariate analysis, PMI, PNI, GNRI, and ALB were found to impact the outcomes of the patients at different follow-up times. However, the predictive value of these nutritional indices was eliminated when established risk factors were considered. In the multivariate analysis that only included nutrition-related indicators, PMI emerged as an independent prognostic factor for 1-year treatment outcomes. The group with low PMI (≤5.5409 cm(2)/m(2)) was found to have a higher risk of death at one year and at the end of the follow-up period. Taylor & Francis 2023-09-20 /pmc/articles/PMC10512869/ /pubmed/37728115 http://dx.doi.org/10.1080/21645515.2023.2258567 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Research Article Luo, Ning Li, Hu Luo, Yindeng Hu, Peng Liang, Luwen Zhang, Rong Zhang, Dazhi Cai, Dachuan Kang, Juan Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title | Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title_full | Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title_fullStr | Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title_full_unstemmed | Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title_short | Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
title_sort | prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512869/ https://www.ncbi.nlm.nih.gov/pubmed/37728115 http://dx.doi.org/10.1080/21645515.2023.2258567 |
work_keys_str_mv | AT luoning prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT lihu prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT luoyindeng prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT hupeng prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT liangluwen prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT zhangrong prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT zhangdazhi prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT caidachuan prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors AT kangjuan prognosticsignificanceofpsoasmuscleindexinmalehepatocellularcarcinomapatientstreatedwithimmunecheckpointinhibitorsandtyrosinekinaseinhibitors |